Antibiotic Resistance in the Treatment of Staphylococcus Aureus Keratitis: a 20-Year Review

Overview

Journal Cornea

Specialty Ophthalmology

Date 2015 Mar 27

PMID 25811722

Citations 65

Authors

Victoria S Chang

Deepinder K Dhaliwal

Leela Raju

Regis P Kowalski

Affiliations

Soon will be listed here.

Abstract

Purpose: We compared the resistance patterns of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible Staphylococcus aureus (MSSA) keratitis isolates with the common topically applied ophthalmic antimicrobials.

Methods: We reviewed the antibiotic susceptibility results of 122 MRSA and 276 MSSA keratitis isolates from January 1993 to November 2012. In vitro susceptibility testing of each Staphylococcus aureus (SA) isolate was performed using Kirby-Bauer disk diffusion based on modified serum interpretations for cefoxitin, bacitracin, cefazolin, ciprofloxacin, gatifloxacin, gentamicin, moxifloxacin, ofloxacin, polymyxin B, sulfamethoxazole, tobramycin, and trimethoprim.

Results: MRSA represented 30.7% (122 of 398) of the total SA isolates. All the SA isolates were susceptible to vancomycin, whereas they were less susceptible to the fluoroquinolones than to the non-fluoroquinolones. In comparison with MSSA, MRSA was significantly more resistant to all the antibiotics tested other than polymyxin B (both equally resistant) and vancomycin (both equally susceptible) (P < 0.001). Besides vancomycin, MRSA demonstrated the best susceptibilities to sulfamethoxazole (94.3%), bacitracin (89.3%), trimethoprim (88.5%), and gentamicin (86.1%). Additionally, MRSA was found to be significantly more resistant to the second-generation fluoroquinolones (ciprofloxacin and ofloxacin) than to the fourth-generation fluoroquinolones (moxifloxacin and gatifloxacin). An increase in resistance to the fourth-generation fluoroquinolones was detected for both MRSA and MSSA over the study period.

Conclusions: The in vitro susceptibilities of commonly used topical antibiotics differ for MRSA and MSSA isolates; thus, successful treatment of bacterial keratitis should be supported with laboratory studies. Vancomycin remains the treatment of choice for MRSA keratitis. The empiric use of second-generation fluoroquinolones seems to be contraindicated in the treatment of MRSA keratitis.

Citing Articles

Inactivation of antibiotic resistant bacteria by nitrogen-doped carbon quantum dots through spontaneous generation of intracellular and extracellular reactive oxygen species.

Xia W, Wu Z, Hou B, Cheng Z, Bi D, Chen L Mater Today Bio. 2025; 30():101428.

PMID: 39850241 PMC: 11754679. DOI: 10.1016/j.mtbio.2024.101428.

Microbiology and management of Staphylococcus aureus lacrimal system infections: A 10-year retrospective study.

Bineshfar N, Clauss K, Lee W, Miller D PLoS One. 2024; 19(11):e0314366.

PMID: 39576782 PMC: 11584140. DOI: 10.1371/journal.pone.0314366.

Effect of chitosan nanogels loaded with vancomycin and gamma interferon on TNF-α gene expression in macrophage cell line activated with methicillin-resistant (MRSA).

Arkiya S, Hesampour A, Esrafili A, Arasteh J Iran J Microbiol. 2024; 16(5):614-623.

PMID: 39534300 PMC: 11551651. DOI: 10.18502/ijm.v16i5.16794.

Microbial keratitis in north-western Spain: a review of risk factors, microbiological profile and resistance patterns.

Lamas-Francis D, Navarro D, Mansilla R, de-Rojas V, Moreno C, Dios E Eur J Clin Microbiol Infect Dis. 2024; 44(1):53-61.

PMID: 39508987 DOI: 10.1007/s10096-024-04978-6.

Activation of pro-resolving pathways mediate the therapeutic effects of thymosin beta-4 during -induced keratitis.

Wang Y, Banga L, Ebrahim A, Carion T, Sosne G, Berger E Front Immunol. 2024; 15:1458684.

PMID: 39380984 PMC: 11458456. DOI: 10.3389/fimmu.2024.1458684.

References

Vola M, Moriyama A, Lisboa R, Vola M, Hirai F, Bispo P . Prevalence and antibiotic susceptibility of methicillin-resistant Staphylococcus aureus in ocular infections. Arq Bras Oftalmol. 2014; 76(6):350-3. DOI: 10.1590/s0004-27492013000600006. View

Elsahn A, Yildiz E, Jungkind D, Abdalla Y, Erdurmus M, Cremona F . In vitro susceptibility patterns of methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus corneal isolates to antibiotics. Cornea. 2010; 29(10):1131-5. DOI: 10.1097/ICO.0b013e3181d2ce25. View

Goldstein M, Kowalski R, Gordon Y . Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999; 106(7):1313-8. View

Oliveira A, DAzevedo P, Francisco W . In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil. Cornea. 2007; 26(2):194-8. DOI: 10.1097/01.ico.0000248379.78777.f6. View

Blomquist P . Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2007; 104:322-45. PMC: 1809917. View

Blot S, Vandewoude K, Hoste E, Colardyn F . Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med. 2002; 162(19):2229-35. DOI: 10.1001/archinte.162.19.2229. View

Hiramatsu K, Ito T, Tsubakishita S, Sasaki T, Takeuchi F, Morimoto Y . Genomic Basis for Methicillin Resistance in Staphylococcus aureus. Infect Chemother. 2013; 45(2):117-36. PMC: 3780952. DOI: 10.3947/ic.2013.45.2.117. View

Kowalski R, Kowalski T, Shanks R, Romanowski E, Karenchak L, Mah F . In vitro comparison of combination and monotherapy for the empiric and optimal coverage of bacterial keratitis based on incidence of infection. Cornea. 2012; 32(6):830-4. PMC: 3568252. DOI: 10.1097/ICO.0b013e318268d6f4. View

Magli A, Forte R, Rombetto L, Carelli R . Bilateral methicillin-resistant Staphylococcus aureus keratitis following hyperopic photorefractive surgery. Int Ophthalmol. 2012; 32(1):47-9. DOI: 10.1007/s10792-011-9505-1. View

10.

Fridkin S, Hageman J, McDougal L, Mohammed J, Jarvis W, Perl T . Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis. 2003; 36(4):429-39. DOI: 10.1086/346207. View

11.

Marangon F, Miller D, Muallem M, Romano A, Alfonso E . Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol. 2004; 137(3):453-8. DOI: 10.1016/j.ajo.2003.10.026. View

12.

Orlans H, Hornby S, Bowler I . In vitro antibiotic susceptibility patterns of bacterial keratitis isolates in Oxford, UK: a 10-year review. Eye (Lond). 2011; 25(4):489-93. PMC: 3171240. DOI: 10.1038/eye.2010.231. View

13.

Freidlin J, Acharya N, Lietman T, Cevallos V, Whitcher J, Margolis T . Spectrum of eye disease caused by methicillin-resistant Staphylococcus aureus. Am J Ophthalmol. 2007; 144(2):313-5. DOI: 10.1016/j.ajo.2007.03.032. View

14.

Zaidi T, Zaidi T, Yoong P, Pier G . Staphylococcus aureus corneal infections: effect of the Panton-Valentine leukocidin (PVL) and antibody to PVL on virulence and pathology. Invest Ophthalmol Vis Sci. 2013; 54(7):4430-8. PMC: 3700385. DOI: 10.1167/iovs.13-11701. View

15.

Entenza J, Hohl P, Glauser M, Moreillon P . BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob Agents Chemother. 2001; 46(1):171-7. PMC: 126986. DOI: 10.1128/AAC.46.1.171-177.2002. View

16.

Fallon M, SHAFER W, Jacob E . Use of cefazolin microspheres to treat localized methicillin-resistant Staphylococcus aureus infections in rats. J Surg Res. 1999; 86(1):97-102. DOI: 10.1006/jsre.1999.5686. View

17.

Shanmuganathan V, Armstrong M, Buller A, Tullo A . External ocular infections due to methicillin-resistant Staphylococcus aureus (MRSA). Eye (Lond). 2004; 19(3):284-91. DOI: 10.1038/sj.eye.6701465. View

18.

Romanowski E, Mah F, Yates K, Kowalski R, Gordon Y . The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in a NZW rabbit model. Am J Ophthalmol. 2005; 139(5):867-77. DOI: 10.1016/j.ajo.2005.01.021. View

19.

Fintelmann R, Hoskins E, Lietman T, Keenan J, Gaynor B, Cevallos V . Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures. Arch Ophthalmol. 2011; 129(4):399-402. PMC: 3830547. DOI: 10.1001/archophthalmol.2011.45. View

20.

Gaynor B, Chidambaram J, Cevallos V, Miao Y, Miller K, Jha H . Topical ocular antibiotics induce bacterial resistance at extraocular sites. Br J Ophthalmol. 2005; 89(9):1097-9. PMC: 1772818. DOI: 10.1136/bjo.2005.068981. View